
via EPFL
Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralizing all variants of concern identified to date, including the delta variant.
Their findings are published in the prestigious journal Cell Reports.
The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV study being carried out by CHUV’s Service of Immunology and Allergy. This antibody is one of the most powerful identified so far against SARS-CoV-2. Structural characterization of the antibody indicates that it binds to an area that is not subjected to mutations of the spike protein. Through this tight interaction, the antibody blocks the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor the virus uses to enter and infect lung cells. That means the antibody halts the viral replication process, enabling a patient’s immune system to eliminate SARS-CoV-2 from the body. This protective mechanism was proven through in vivo tests on hamsters; specimens that were administered the antibody were protected against infection even after receiving a highly infectious dose.
In addition to its antiviral properties, the new antibody is designed to have a lasting effect in humans. A typical unaltered antibody provides protection for up to 3–4 weeks. But this new one can protect patients for 4–6 months. That makes it an interesting preventive-treatment option for unvaccinated at-risk individuals or for vaccinated individuals who are unable to produce an immune response. Immunocompromised patients, organ transplant recipients and those suffering from certain kinds of cancer could be protected against SARS-CoV-2 by receiving antibody injections two or three times a year.
CHUV and EPFL now plan to build on these promising results in association with a start-up company which will perform clinical development and production of the antibody-containing drug, through cooperation and intellectual property agreements. Clinical trials of the drug should begin in late 2022.
Treatment or prophylaxy
This research was conducted jointly by CHUV’s Service of Immunology and Allergy, headed by Prof. Giuseppe Pantaleo and Dr. Craig Fenwick, and by EPFL’s Laboratory of Virology and Genetics, headed by Prof. Didier Trono and Dr. Priscilla Turelli. The research team was able to respond to the pandemic and discover this neutralizing antibody so quickly thanks to the multi-year support of the Swiss Vaccine Research Institute. Prof. Pantaleo’s department at CHUV also received support from the Corona Accelerated R&D in Europe (CARE) program, which is part of the Innovative Medicine Initiative (IMI) – a public-private partnership that seeks to address bottlenecks in the drug discovery and development process in Europe.
The discovery of this new antibody marks a major step forward in the fight against COVID-19. It opens the door to improved treatments for severe forms of the disease and to enhanced prophylactic measures, especially for patients with weakened immune systems. However, this antibody is not intended to replace COVID-19 vaccines, which remain the most effective way to prevent infection.
Original Article: Scientists discover a highly potent antibody against SARS-CoV-2
More from: École Polytechnique Fédérale de Lausanne | Lausanne University Hospital
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Monoclonal antibody
- Nipah virus outbreak: What are monoclonal antibodies?
According to a research paper published in October 2020, the m102.4 monoclonal antibody binds itself to the immunodominant receptor-binding glycoprotein of the Nipah virus, potentially neutralising it ...
- ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats
The awarded funding will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology. MSTAR is a flexible plug-and-play ...
- Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
- Monoclonal antibody may cure advanced rabies, animal study finds
Researchers now think they've found an effective and simple treatment that can cure even advanced cases of rabies.
- Ono and Adimab partner to develop oncology antibody drugs
Adimab will receive an up-front payment, research and development funding, and success-based milestone payments from Ono.
Go deeper with Google Headlines on:
Monoclonal antibody
[google_news title=”” keyword=”monoclonal antibody” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
SARS-CoV-2 monoclonal antibody
- Nipah virus outbreak: What are monoclonal antibodies?
According to a research paper published in October 2020, the m102.4 monoclonal antibody binds itself to the immunodominant receptor-binding glycoprotein of the Nipah virus, potentially neutralising it ...
- SARS-CoV-2 Infects Coronary Arteries, Increases Plaque Inflammation
NIH-funded research sheds light on link between COVID-19 infection and increased risk of cardiovascular disease and stroke. SARS-CoV-2, the virus that causes COVID-19, can directly infect the arteries ...
- Dr. William Petri, a UVa immunologist, answers questions about COVID and vaccination needs
If you had COVID or the old booster recently, it makes sense to wait for three to four months after to be vaccinated.
- Antiviral peptide prevents SARS-CoV-2 from infecting host cells
Emory Vaccine Center researchers say they have identified the Achilles heel of SARS-CoV-2, the virus that causes COVID-19.
- Longhorn Vaccines and Diagnostics Presents Data Demonstrating Neutralizing Activity of LHNVD-201 for Covid-19 and Influenza Co-Infections
Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today ...
Go deeper with Google Headlines on:
SARS-CoV-2 monoclonal antibody
[google_news title=”” keyword=”SARS-CoV-2 monoclonal antibody” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]